1. Home
  2. FRD vs PYXS Comparison

FRD vs PYXS Comparison

Compare FRD & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Friedman Industries Inc.

FRD

Friedman Industries Inc.

HOLD

Current Price

$34.66

Market Cap

134.3M

Sector

Industrials

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$1.80

Market Cap

124.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRD
PYXS
Founded
1965
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.3M
124.2M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
FRD
PYXS
Price
$34.66
$1.80
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
23.5K
529.4K
Earning Date
06-11-2026
05-13-2026
Dividend Yield
0.79%
N/A
EPS Growth
N/A
3.03
EPS
1.46
N/A
Revenue
$121,157,278.00
$13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,043.98
P/E Ratio
$18.07
N/A
Revenue Growth
55.82
N/A
52 Week Low
$14.52
$0.97
52 Week High
$26.50
$5.55

Technical Indicators

Market Signals
Indicator
FRD
PYXS
Relative Strength Index (RSI) 92.37 48.56
Support Level $17.90 $1.60
Resistance Level N/A $2.17
Average True Range (ATR) 1.36 0.18
MACD 0.75 -0.01
Stochastic Oscillator 89.50 50.69

Price Performance

Historical Comparison
FRD
PYXS

About FRD Friedman Industries Inc.

Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: